PedAM
Pediatric Disease Annotations & Medicines
| Disease | schizophrenia |
| Phenotype | C0007222|cardiovascular disease |
| Sentences | 13 |
| PubMedID- 21964485 | C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. |
| PubMedID- 20079332 | cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. |
| PubMedID- 26528652 | Objective: metabolic and cardiovascular diseases in patients with schizophrenia have gained a lot of interest in recent years. |
| PubMedID- 20923921 | Although the highest number of excess deaths in schizophrenia is associated with cardiovascular disease, people with schizophrenia have low rates of surgical interventions such as stenting and bypass grafting (druss et al., 2000; kisely et al., 2007; lawrence et al., 2003; laursen et al., 2009). |
| PubMedID- 25542737 | The purpose of this study is to investigate the relationship between total and differential white blood cell (wbc) counts, hscrp, and indices of cardiovascular disease risk in patients with schizophrenia and related non-affective psychoses. |
| PubMedID- 24710015 | Most antipsychotic medications are associated with an increased risk for metabolic disturbances, such as weight gain, obesity, diabetes, hyperlipidemia, which ultimately contribute to an increased risk for cardiovascular disease in patients with schizophrenia [25]. |
| PubMedID- 23515714 | Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in german psychiatric hospitals: results of the pharmacoepidemiologic cats study. |
| PubMedID- 24143102 | To our knowledge, the present study is the first to demonstrate an increased risk for cardiovascular disease in patients with schizophrenia via methods of abi, cimt, and tissue doppler echocardiography. |
| PubMedID- 23225174 | In order to reduce the risk of cardiovascular disease in patients with schizophrenia receiving antipsychotic agents, obtaining fasting lipid measurements at regular intervals is needed. |
| PubMedID- 23599376 | This suggests a systematic under-recognition and undertreatment of cardiovascular disease in people with schizophrenia, which might contribute to substantial premature mortality observed within this patient group. |
| PubMedID- 23982303 | The overlap in genetic risk is important since there is significant mortality from cardiovascular disease in patients with schizophrenia suggesting the need to better monitor cardiovascular disease in these patients (gegenava and kavtaradze, 2006; laursen et al., 2012). |
| PubMedID- 26001844 | Protocol for change: a randomized clinical trial assessing lifestyle coaching plus care coordination versus care coordination alone versus treatment as usual to reduce risks of cardiovascular disease in adults with schizophrenia and abdominal obesity. |
| PubMedID- 24143103 | Considering the increased rates of cardiovascular diseases in patients with schizophrenia compared with the normal population, these findings are noteworthy. |
Page: 1